Royal Bank of Canada raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 40.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,131 shares of the biopharmaceutical company’s stock after buying an additional 2,648 shares during the quarter. Royal Bank of Canada’s holdings in Agios Pharmaceuticals were worth $470,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in AGIO. BlackRock Inc. increased its holdings in Agios Pharmaceuticals by 8,463.5% in the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock valued at $126,556,000 after buying an additional 2,141,768 shares during the period. FMR LLC increased its holdings in Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after buying an additional 895,584 shares during the period. Vanguard Group Inc. increased its holdings in Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after buying an additional 617,379 shares during the period. First Trust Advisors LP increased its holdings in Agios Pharmaceuticals by 52.3% in the 2nd quarter. First Trust Advisors LP now owns 973,870 shares of the biopharmaceutical company’s stock valued at $50,106,000 after buying an additional 334,291 shares during the period. Finally, PDT Partners LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter valued at about $9,565,000. 93.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Agios Pharmaceuticals, Inc. (AGIO) opened at $61.96 on Tuesday. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. During the same period last year, the company posted ($1.63) EPS. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $56.85, for a total transaction of $227,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $62.69, for a total transaction of $134,532.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 178,908 shares of company stock worth $12,147,719. 10.55% of the stock is owned by corporate insiders.

Several equities analysts have commented on AGIO shares. Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Needham & Company LLC raised their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, August 10th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $75.70.

TRADEMARK VIOLATION NOTICE: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/14/agios-pharmaceuticals-inc-agio-holdings-boosted-by-royal-bank-of-canada.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.